Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17757679 | 0.94 | SIGMAR1 (0.32) | SIGMAR1CCNT1CDK9 | |
| SCHEMBL17757144 | 0.86 | CCNT1 (0.33) | CCNT1CDK9 | |
| SCHEMBL17757138 | 0.83 | OPRM1 (0.36) | — | |
| SCHEMBL21982532 | 0.80 | CCNT1 (0.34) | SIGMAR1CCNT1 | |
| SCHEMBL17757671 | 0.80 | GRM2 (0.36) | CCNT1CDK9 | |
| SCHEMBL17757142 | 0.79 | OPRM1 (0.33) | CDK9 | |
| SCHEMBL17757147 | 0.79 | CCNT1 (0.35) | CCNT1PDE1APDE1BPDE4DPDE7A | |
| SCHEMBL17757140 | 0.79 | HRH4 (0.39) | — | |
| SCHEMBL17757659 | 0.78 | CCNT1 (0.40) | CCNT1CDK9 | |
| SCHEMBL17757146 | 0.78 | CHRNA7 (0.35) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | PDE7B 3724/4885GRM4 892/4885SIGMAR1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.